Develops psychedelic-inspired medicines for mental health disorders, focusing on treatments that target the psychedelic experience for therapeutic benefits.
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for brain health disorders. These include psychiatric conditions, addiction, pain, and neurological issues. One of their leading products, MM-120, is currently in phase 2 trials for generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for chronic pain management. Additionally, they are advancing MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 trials aimed at treating opioid withdrawal symptoms.
MindMed is also working on MM-402, which is a R-enantiomer of 3,4-methylenedioxymethamphetamine. This compound is being developed to address the core symptoms associated with autism spectrum disorder. The company's diverse portfolio underscores its commitment to addressing unmet medical needs through innovative approaches in psychopharmacology and neurology.
Headquartered in New York, New York, MindMed is at the forefront of leveraging cutting-edge science to develop next-generation therapies. With a robust pipeline and a focus on mental health and neurological conditions, the company aims to make significant contributions to improving patient outcomes and quality of life.